US Edition
News from The AI Journal
We’ve assigned a rating of Unknown factuality to The AI Journal. You can read more about how we’ve determined The AI Journal’s credibility and reliability as a news source here: https://groundnews.lakegeneva.lib.wi.us/rating-system.
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top The AI Journal News
Artificial Intelligence · United StatesBy Clare Duffy, CNN New York (CNN) — The US government is launching an early career hiring and talent development program to bring more technology and artificial intelligence employees to the public sector, as part of the Trump administration’s efforts to modernize government systems and stay ahead in the global tech race. The launch of the “US Tech Force” is designed to address a technical and early career talent gap across the government, acco…See the Story
Trump admin to hire 1,000 specialists for ‘Tech Force’ to build AI, finance projects
52% Center coverage: 34 sources
Tokyo, Japan · TokyoTOKYO, Dec. 16, 2025 /PRNewswire/ -- Polyplastics Co., Ltd., a global leader in engineering thermoplastics, has expanded its LAPEROS(R) liquid crystal polymer (LCP) product line with the launch of the new LH and TF series materials, which meet the electronics…See the Story
Polyplastics Expands LAPEROS(R) LCP Range to Meet Demands of Electronics Industry
61% Center coverage: 34 sources
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
